Search results
Search for "nanoliposomes" in Full Text gives 10 result(s) in Beilstein Journal of Nanotechnology.
Influence of surface characteristics on the in vitro stability and cell uptake of nanoliposomes for brain delivery
Beilstein J. Nanotechnol. 2026, 17, 139–158, doi:10.3762/bjnano.17.9
- neurons (ranging from 25.17% to 27.54%). Fluorescence and confocal microscopy micrographs revealed that, once internalized, NLs were concentrated in the perinuclear cell regions. Keywords: blood–brain barrier; cell co-culture; cell uptake; internalization; nanoliposomes; stability; surface
- characteristics; Introduction Advancements in nanotechnology and the use of nanoliposomes (NLs) as carriers for targeted delivery and controlled release of active components (AC) show promise in addressing multiple pathologies associated with neurodegenerative diseases like Alzheimer's disease (AD) [1]. It is
- '-tetramethylindocarbocyanine perchlorate ('DiI'; DiIC18(3))) were purchased from Thermo Fisher Scientific (California, USA). All chemicals and reagents used were of the highest purity grade commercially available. Preparation of the nanoliposomes Nanoliposome samples (SL:CH:PEG = 8.71:1:0; 8.71:1:1.67, and 8.71:1:0.67 molar
Ferroptosis induction by engineered liposomes for enhanced tumor therapy
Beilstein J. Nanotechnol. 2025, 16, 1325–1349, doi:10.3762/bjnano.16.97
Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy
Beilstein J. Nanotechnol. 2025, 16, 97–118, doi:10.3762/bjnano.16.10
- microenvironment. An innovative approach involves “tail-flipping” nanoliposomes incorporating carboxylated phospholipids, such as 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAPC), designed to selectively target M2 TAMs via scavenger receptors, such as SR-B1. When loaded with therapeutic agents such as the
- STAT6 inhibitor AS1517499, zoledronic acid, or muramyl tripeptide (MTP), these liposomes inhibited M2 polarization. In preclinical breast cancer models, PAPC nanoliposomes reduced tumor growth, inhibited the M2 phenotype, and prevented pre-metastatic niche formation, achieving up to a 70% reduction in
Nanotechnological approaches for efficient N2B delivery: from small-molecule drugs to biopharmaceuticals
Beilstein J. Nanotechnol. 2024, 15, 1400–1414, doi:10.3762/bjnano.15.113
- situ esculin-loaded nanoliposomes for intranasal administration for treating Parkinson’s disease. Ex vivo studies further confirmed the enhanced permeation of the nanoliposomal formulation compared to the suspension form by approximately 40% [99]. Solid lipid NPs and nanostructured lipid carriers Solid
Cholesterol nanoarchaeosomes for alendronate targeted delivery as an anti-endothelial dysfunction agent
Beilstein J. Nanotechnol. 2024, 15, 517–534, doi:10.3762/bjnano.15.46
- -O-phytanylglycerol] (SDGD-5PA) (Figure 1). Preparation and characterization of nanovesicles In a manner analogous to [29], nanoarchaeosomes made of TPA (nanoARC) and of TPA/Chol 7:3 w/w (nanoARC-Chol), and nanoliposomes made of HSPC/Chol 7.5:2.5 w/w, were prepared by the film hydration method. To
Classification and application of metal-based nanoantioxidants in medicine and healthcare
Beilstein J. Nanotechnol. 2024, 15, 396–415, doi:10.3762/bjnano.15.36
- : (1) nanoliposomes, which are a nanoscale bilayer lipid vesicle [132]; (2) nanocapsules, which consist of an inner aqueous core surrounded by a nontoxic polymeric membrane [133]; (3) solid lipid nanoparticles, which consist of a solid lipid core stabilized by a surfactant [134]; and (4) nanocrystals
Nanomedicines against Chagas disease: a critical review
Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30
- nanoliposomes of etanidazole (a soluble 2-nitroimidazole; 0.63 mg etanidazole/kg/day in nine total doses, three doses per week over three weeks: 5.67 mg etanidazole/kg TD) reduced trypomastigotes in blood of an acute murine model infected with T. cruzi RA strain [69], to the same extent as orally administered
Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review
Beilstein J. Nanotechnol. 2024, 15, 37–50, doi:10.3762/bjnano.15.4
- systems [19], nanoparticles [20], nanoliposomes [21], micelles [22], and nanocrystals [23] have been utilized. These systems can promote (i) protection of the drug against degradation in physiological media, (ii) increase in drug solubility, and (iii) modification/targeting of the drug enabling transport
- , the amount of parasites in the lymph nodes (31.5%) and footpad (60.3%) decreased [57]. Another nanostructured platform explored for the delivery of leishmanicidal drugs is the liposomal platform [74]. Artemisinin-loaded nanoliposomes smaller than 100 nm were obtained and evaluated in a murine model
- (SNEDDSs), (ii) nanoliposomes, (iii) nanostructured lipid carriers, (iv) polymeric, and (v) metallic nanoparticles. Different performances of nanostructured systems containing curc are discussed in the section below. Self-nanoemulsifying drug-delivery systems The SNEDDSs are lipid-based drug-delivery
Nanotechnological approaches in the treatment of schistosomiasis: an overview
Beilstein J. Nanotechnol. 2024, 15, 13–25, doi:10.3762/bjnano.15.2
- , Adekiya et al. [40] produced PZQ encapsulated in nanoliposomes whose surface was modified with an antibody against calpain, a protein found in the tegument of the parasite and is upregulated in the regions where host–parasite interaction occurs [41]. The modified nanoparticles orally administered two or
Elasticity, an often-overseen parameter in the development of nanoscale drug delivery systems
Beilstein J. Nanotechnol. 2023, 14, 1149–1156, doi:10.3762/bjnano.14.95
- comparable size and surface characteristics but variable Young’s moduli ranging from 45 kPa to 19 MPa. In contrast to many other studies, soft nanoliposomes (NLPs) are taken up better by cells than harder particles used in this study. This is explained by the combination of membrane fusion and clathrin
Other Beilstein-Institut Open Science Activities
